The impact of PPAR variants on the susceptibility to NASH in specific subgroup of patients, and in particular on the response to therapies, especially those targeting PPARs, represents promising new areas of investigation. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.